The Safety and Efficacy of Ozarelix to Treat Men With Lower Urinary Tract Symptoms Due to Enlargement of the Prostate

Benign Prostatic Hypertrophy Clinical Trial

Official title:

A Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of Ozarelix, in Patients With Lower Urinary Tract Symptoms(LUTS) Due to Benign Prostatic Hypertrophy (BPH)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00427219
• Other study ID #: SPI-153-06-1
• Status: Completed
• Phase: Phase 2
• Start date: January 23, 2007
• Est. completion date: February 27, 2008

Study information

• Verified date: October 2021
• Source: Spectrum Pharmaceuticals, Inc
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is to compare the efficacy and safety of ozarelix 15 mg given intramuscular (IM) 2 weeks apart on the improvement of symptoms and the duration of improvement for up to 6 months in men with Benign Prostatic Hypertrophy (BPH) who are over 50 years of age.

Description:

This study is to compare the improvement in symptom scores, peak flow rate and quality of life in men suffering from lower urinary tract symptoms (LUTS) secondary to Benign Prostatic Hypertrophy (BPH) following treatment with ozarelix. Ozarelix is compared to placebo and injections given 14 days apart. Patients are followed for 6 months and both safety and efficacy assessed at monthly visits. Additionally, the impact of treatment on erectile function, if any, as well as Prostate-Specific Antigen (PSA) and Testosterone levels will be monitored.

The screening period of 7 days. The duration of the study is 40 weeks, including a 28-day placebo run-in phase (eligible participants entered a placebo run-in phase in which placebo is administered twice over a 2 week period [Day -28 and Day -14] and participants are assessed to establish baseline values approximately 14 days following the second placebo injection), study drug is administered on Days 0 and 14 followed by 34 weeks of observation after the last dose of study drug.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 74
• Est. completion date: February 27, 2008
• Est. primary completion date: February 27, 2008
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 50 Years and older

Eligibility

Inclusion Criteria:

• All of the following questions must be answered "Yes" at Visit 1 in order for the participant to participate in the study.

• Is the participant at least 50 years old?

• Does the participant have clinical signs and symptoms consistent with BPH?

• Does the participant have an IPSS 13 at screening (prior to placebo run in)?

• Does the participant have a peak urinary flow rate (Qmax) of 4-15 milliliter/second (mL/sec) established on a voided volume of at least 125 mL?

• Is the participant willing to agree not to use any other approved or experimental pharmacologic BPH treatments including alpha blockers, 5-alpha reductase inhibitors, anti-cholinergic preparations or herbal preparations at any time during the study?

Exclusion Criteria: All of the following questions must be answered "No" at Visit 1 in order for the participant to participate in the study.

• Does the participant have a history of prostate cancer or a serum PSA >10 nanograms per milliliter (ng/mL)?

• Has the participant had prior prostate or bladder surgery, pelvic surgery (excluding hernia repair), pelvic radiation or lower urinary tract malignancy?

• Does the participant have a prevoid total bladder volume assessed by ultrasound > 550 mL?

• Does the participant have a residual urine volume > 350 mL by ultrasound?

Related Conditions & MeSH terms

• Benign Prostatic Hypertrophy
• Hypertrophy
• Lower Urinary Tract Symptoms
• Prostatic Hyperplasia

Intervention

Drug:
• Ozarelix
Ozarelix 15 mg will be administered IM on Day 0 and Day 14.
• Placebo
Placebo will be administered IM on Day 0 and Day 14.

Locations

Country	Name	City	State
United States	Joel Kaufman, MD	Aurora	Colorado
United States	Christopher Steidle, MD	Fort Wayne	Indiana
United States	Jay Young, MD	Laguna Hills	California
United States	Alexander Gershman, MD	Los Angeles	California
United States	Joseph Williams, MD	Meridian	Idaho
United States	Jed Kaminetsky, MD	New York	New York
United States	Stephen Auerbach, MD	Newport Beach	California
United States	Ira Klimberg, MD	Ocala	Florida
United States	Steven Bigg, MD	Saint Louis	Missouri
United States	William Fitch, MD	San Antonio	Texas
United States	Eugene Dula, MD	Tarzana	California
United States	Donald Gleason, MD	Tucson	Arizona
United States	Gregg Eure, MD	Virginia Beach	Virginia

Sponsors (1)

Lead Sponsor	Collaborator
Spectrum Pharmaceuticals, Inc

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change From Baseline in International Prostate Symptom Score (IPSS)	IPSS is a validated self-administered index for grading benign prostatic hyperplasia (BPH)-related signs and symptoms. It consists of a set of seven questions. A total score of 1-7 indicates mild disease, 8-19 moderate disease and 20-35 severe disease.	12 weeks
Secondary	International Prostate Symptom Score - Quality of Life (IPSS-QOL)	IPSS QOL is a disease-specific quality of life question, referred to as IPSS Question 8. Participants with an IPSS QOL of <3 at screening will be excluded from this study. The rating is as follows: 0=delighted, 1=pleased, 2=mostly satisfied, 3=mixed, 4=mostly dissatisfied, 5=unhappy, 6=terrible.	36 weeks
Secondary	BPH Impact Index (BPHII)	BPH Impact Index (BII) is used to assess the impact of BPH on various aspects of health. This 4 question self administered index uses a scoring range from 0 (best) to 13 (worst).	36 weeks
Secondary	Lower Urinary Tract Symptoms (LUTS) Global Assessment Question (LUTS-GAQ)	The self administered LUTS GAQ is a "yes" or "no" response to a question asking whether overall improvement in LUTS will be observed during the treatment period.	36 weeks
Secondary	International Index of Erectile Function-15 (IIEF-15)	International Index of Erectile Function Erectile Function Domain (IIEF-EF) will be used to assess the effect of ozarelix on erectile function in sexually active men. IIEF-EF is defined as the sum of the scores for Questions 1-5 and 15 of the IIEF questionnaire. This recall instrument is self-administered by the participant. Individual questions are graded from 1 to 5 with a maximum total score of 30. Lower IIEF-EF scores represent diminished erectile function. Men with a score of = 26 are interpreted as having normal erectile function.	36 weeks
Secondary	Maximum Urinary Flow Rate (Qmax)	Qmax was measured by free flow uroflowmetry. Qmax is defined as the peak urine flow rate (measured in milliliter (mL)/second using a standard calibrated flowmeter). For a Qmax to be considered valid, the voided volume had to be at least 125 mL. The uroflowmeter is to be calibrated weekly.	36 weeks
Secondary	Number of Participants With Adverse Events		36 weeks